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 55 
To the Editors, 56 
  expert guidelines now recommend immediate antiretroviral therapy 57 
(ART) for all HIV-infected persons regardless of CD4 cell count, to reduce the risk of 58 
disease progression and prevent HIV transmission.1, 2 There is also increasing 59 
evidence that very early ART benefits the individual infected with HIV by leading to 60 
more rapid and robust immunologic recovery, lower inflammation and reduced viral 61 
reservoir size compared to a later start.3-12 However, in low and middle income 62 
countries universal immediate ART is rarely available. To assist clinicians in regions 63 
were universal ART is not available in prioritizing provision of immediate ART to 64 
patients that benefit most , Braun and colleagues recently developed the Acute 65 
Retroviral Syndrome Severity Score (ARSSS). Following the hypothesis that severity 66 
of primary HIV infection correlates with disease progression13-17, the score includes 67 
mostly clinical variables which reflect the intensity of the clinical presentation of 68 
primary HIV infection.18 The score was evaluated retrospectively among 290 69 
individuals of the Zurich primary HIV infection study and correlated well with validated 70 
surrogate markers associated with HIV-1 disease progression, i.e. baseline CD4+ cell 71 
count, baseline viral load and setpoint viral load.18 External validation of the ARSSS 72 
is still missing, however. Further it remains unclear if the score has predictive validity 73 
also in individuals at the earliest stage of HIV infection, as only 3 out of these 290 74 
Copyright  2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
  
individuals fulfilled the earliest criteria of acute HIV infection (AHI; i.e. Fiebig I or II).18, 75 
19
 76 
          In this retrospective analysis of a prospective observational cohort study, we 77 
evaluated performance of the ARSSS 18 in persons diagnosed with AHI between 78 
2007 and 2014 by the San Diego Primary HIV Infection Consortium.20 A total of 90 79 
persons were identified with AHI and provided questionnaire responses on signs and 80 
symptoms of ARS at the time of AHI diagnosis, though only the subset of 48 81 
individuals who provided information on whether they had sought medical attention 82 
for signs or symptoms of acute retroviral syndrome (i.e., a substantial 3-point 83 
component of the ARSSS) were included in this analysis (the question was not 84 
included in the questionnaire used between 2010 and 2012). All individuals were 85 
diagnosed with AHI with the “Early Test” that included routine individual donation 86 
(ID), HIV nucleic acid amplification testing (ID-NAT) to all rapid antibody–negative 87 
participants.21-26 AHI was defined as having a negative or indeterminate HIV antibody 88 
test result with a positive ID-NAT, corresponding to Fiebig stages I–II, and a mean 89 
estimated duration of infection of 10 days.19 At each participant’s first visit after 90 
documentation of AHI diagnosis (median 4 days, interquartile range [IQR] 3–6 days 91 
after AHI testing), blood samples were collected for CD4 and viral load testing. 92 
Detailed information related to occurrence, duration, and start and stop dates for 93 
signs and symptoms associated with AHI were also collected.27, 28 Participants were 94 
asked if they had sought medical attention for any of these signs or any symptoms. In 95 
persons who reported symptoms that were ongoing, the date on which symptoms 96 
resolved as well as additional signs or symptoms occurring within 4 weeks after the 97 
AHI test were collected during follow-up.20 The viral setpoint was defined as the first 98 
Copyright  2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
  
HIV-RNA measurement ≥90 days after the estimated date of infection in treatment-99 
naive patients.18 100 
We evaluated two versions of the ARSSS, the complete six variable27 ARSSS 101 
assessment (ARSSS-full) in a subset of 19 participants and a shorted version 102 
(ARSSS-short) consisting of four variables in all 48 participants (Table 1).  103 
For this evaluation one of the originally proposed variables, “inpatient 104 
treatment” (i.e. 3 points in ARSSS), was replaced by “seeking medical attention 105 
because of signs and symptoms of acute retroviral syndrome (ARS)”, as inpatient 106 
treatment was not assessed in our cohort undergoing community based testing. The 107 
other three variables of the ARSSS-short, namely presence of severe neurological 108 
symptoms (e.g., encephalitis, meningitis; 3 points), age ≥ 50 years (1 point), and 109 
fever (self-reported or documented ≥38˚ degrees celsius; 1 point) remained 110 
unchanged and were assessed at the first visit after AHI diagnosis in all 48 111 
individuals.  112 
The ARSSS-full consisting of all six variables was assessed in the subset of 113 
19/48 (40%) of participants who had safety lab results available (i.e. those who 114 
initiated ART immediately after AHI diagnosis; lab results were always obtained 115 
before ART start).  116 
For statistical analysis, SPSS version 23 (SPSS, Inc.,Chicago, IL, USA) was 117 
used. Correlation between ARSSS-short and ARSSS-full and viral loads, CD4/CD8 118 
cell ratios, setpoint viral loads and number and duration of symptoms of ARS were 119 
calculated using Spearman correlation analysis due to the non-normal distributions of 120 
ARSSS and lab values. The University of California San Diego’s Human Research 121 
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Protections Program approved the study protocol, consent process, and all study-122 
related procedures.  123 
The study cohort was composed of 48 participants with AHI. All 48 were men 124 
who have sex with men (MSM) Characteristics of the study cohort are displayed in 125 
Table 1. The most frequently reported symptom was fever (71%), followed by fatigue 126 
(67%) and myalgia (58%). 127 
The cohort had a median ARSSS-short of 1 (range 0-7; 23% had a score of 0, 128 
48% a score of 1, each 4% a score of 2 and 3, and 21% a score of 4 or above; Table 129 
1). The ARSSS-short was significantly negatively correlated with CD4/CD8 cell ratio 130 
(Spearman ρ= -0.293; p=0.043) and positively correlated with viral load (ρ= 0.505; 131 
p<0.001). Significant positive correlations were also observed between the ARSSS-132 
short and number of signs and symptoms of ARS (ρ= 0.567; p<0.001) and the total 133 
duration of signs and symptoms of ARS (ρ= 0.398; p=0.007). No significant 134 
correlations were observed between ARSSS-short and CD4 cell count (ρ= -0.045; 135 
p>0.2) and set point viral load (available in those 25/48 participants who started ART 136 
≥ 90 days after EDI; ρ= -0.064; n.s.). Those with ARSSS-short > 2 had significantly 137 
lower CD4/CD8 cell ratios, higher viral loads, longer duration of symptoms and a 138 
trend towards more signs and symptoms than those with scores ≤ 2 (results and p 139 
values calculated using Mann-Whitney U test are depicted in Table 1). 140 
In the 19 individuals with available safety labs, the ARSSS-full (median 1, 141 
range 0-8) did not correlate significantly with viral load (ρ= 0.315; p=0.19), CD4/CD8 142 
cell ratio (ρ= 0.037; p>0.2) or CD4 count (ρ= -0.039; p>0.2). While a significant 143 
correlation was observed between ARSSS-full and number of signs and symptoms 144 
(ρ= 0.543; p=0.024), there was no significant correlation with duration of signs and 145 
Copyright  2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
  
symptoms (ρ= 0.300; p>0.2). Correlations of the ARSSS-short in the subset were as 146 
follows: viral loads (ρ= 0.463; p=0.046), CD4/CD8 ratios (ρ= -0.073; n.s.), CD4 (ρ= -147 
0.063; n.s.), number of signs and symptoms (ρ= 0.418; n.s.), and duration of signs 148 
and symptoms (0.433; n.s.). 149 
 150 
We evaluated the ARSSS, a score to identify individuals with the most severe 151 
clinical presentations of ARS who might profit most of immediate ART, among 48 152 
individuals with AHI with an EDI of 10 days at the time of HIV diagnosis. We found 153 
that the short version of the score, limited to age and clinical variables that can all be 154 
collected at the time of HIV diagnosis, correlated well with severity of ARS in our 155 
study cohort, with significant positive correlations between ARSSS-short and viral 156 
load, number of ARS signs and symptoms and total duration of signs and symptoms, 157 
and a negative correlation between ARSSS-short and CD4/CD8 cell ratios. After 158 
being validated in another study the ARSSS-short may therefore be used to predict 159 
diseases severity at the time of HIV diagnosis and therefore significantly earlier than 160 
other markers of disease severity. While immediate ART for all AHI cases is clearly 161 
preferable and reflects current recommendations 1, 2, a ARSSS cutoff >2 may be 162 
used for immediate treatment in resource limited setting, where drug use has to be 163 
triaged and is available for only about 25% of AHI cases. 164 
The ARSSS-full (which includes the ARSSS-short variables, plus platelet 165 
count and transaminases18) could only be evaluated in the subset of participants. 166 
Interestingly, integration of laboratory variables into the score in this subset did not 167 
improve performance of the score when compared to the ARSSS-short (i.e. 168 
consisting of clinical variables only). This finding may relate to the small sample size 169 
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of the subset with safety labs. Previous studies have shown that low platelet 170 
count29,30 and elevated transaminases31 correlate with HIV 1 disease progression in 171 
individuals with recent and chronic HIV infection. However, the prognostic potential of 172 
these two laboratory values specifically in the earliest stages of HIV infection (i.e. 173 
Fiebig I and II) has not been evaluated.  174 
In conclusion, the ARSSS-short, which includes four easily assessed clinical 175 
and demographic variables, may provide a simple and reliable severity score for 176 
ARS, and may help identify individuals with the greatest risk of disease progression 177 
who would benefit the most from early ART. After validation in another study the 178 
ARSSS-short may therefore help to prioritize treatment in regions where ART is not 179 
universally available. 180 
 181 
 182 
 183 
 184 
 185 
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Table 1: Short version and full version of the Acute Retroviral Syndrome Severity (ARSS) 
Score, demographics and clinical characteristics of the study population and comparison of 
sub-cohorts with Short ARSSS >2 and ≤2. 
 
Scores Variables Individuals 
fulfilling 
variables of the 
score (n, %) 
Short ARSS 
Score  
 
(maximum 
value 8 points) 
1.) Seeking medical attention because of signs and 
symptoms of ARS (3 points) * 
2.) Presence of severe neurological symptoms (3 
points) 
3.) Age ≥ 50 years (1 point) 
4.) Fever (self-reported or documented ≥38˚ 
degrees Celsius; 1 point)  
 
12/48 (25%) 
 
1/48 (2%) 
 
4/48 (8%) 
30/48 (63%) 
Full ARSS 
Score 
(maximum 
value 10 
points) 
      All variables of the short ARSS score PLUS 
5.) Elevated liver enzymes (AST and/or ALT ≥30 
U/l; 1 point) 
6.) Thrombocytopenia (platelet count <150 G/l; 1 
point) 
 
6/19 (32%) 
 
2/19 (11%) 
Demographics and 
Clinical 
Characteristics 
Study cohort Sub-cohort with 
ARSSS-short ≤2 
Sub-cohort with 
ARSSS-short >2 
p-value if <0.1# 
N 48 36 12 - 
Sex (Male/Female) 48 (100%) / 0  36 (100%) / 0 12 (100%) / 0 - 
Age, years (median, 
interquartile range) 
34 (18-69) 35 (25-44) 32 (27-44) - 
Hispanic Ethnicity 14 (29%) 10 (28%) 4 (33%) - 
Caucasian Race 25 (52%) 19 (53%) 6 (50%) - 
Asian Race 3 (6%) 2 (6%) 1 (8%) - 
Black Race 3 (6%) 2 (6%) 1 (8%) - 
Pacific Islander Race 3 (6%) 3 (8%) 0 - 
Clinical 
Characteristics at the 
time of sample 
collection 
median, 
range  
median, 
interquartile 
range  
median, 
interquartile 
range 
p-value if <0.1# 
CD4+ cell count 
(cells/µL) 
465 (120-972) 474 (280-625) 458 (342-555) - 
CD8+ cell count 
(cells/µL) 
602 (91-2831) 545 (269-862) 943 (422-1451) 0.048 
CD4+/CD8+ cell ratio  0.76 (0.13-
2.84) 
0.92 (0.59-1.24) 0.55 (0.33-0.72) 0.032 
Viral load log10 RNA 5.07 (2.53-
7.47) 
4.12 (3.60-4.86) 5.56 (3.66-6.19) 0.002 
Set-point Viral load 
log10 RNA (n=25) 
4.45 (3.32-
6.00) 
§ § § 
Number of signs and 
symptoms 
5 (1-10) 5 (2-6) 7 (5-8) 0.056 
Duration of signs and 
symptoms (days) 
11 (2-32) 7 (4-12) 14 (11-22) 0.006 
Abbreviations: ALT, alanine aminotransferase; ARS, acute respiratory syndrome; AST aspartate 
aminotransferase.  
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was not available. 
# P value calculated using Mann-Whitney U test. 
§ Set-point Viral load was determined in only 2 patients with ARSSS-short >2. Therefore results are not 
displayed. 
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